Sugi Predict

Sugi Predict / Compounds / SCHEMBL2238814

SCHEMBL2238814

SCHEMBL2238814

O=C(O)[C@@H]1C[C@@H](C2CCCCC2)CN1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ SLC1A3 P43003 1/20 0.50
▸ SLC1A2 P43004 1/20 0.50
▸ SLC1A1 P43005 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ GRIK1 P39086 4/20 0.43
▸ GRIA1 P42261 3/20 0.43
▸ GRIA2 P42262 3/20 0.43
▸ GRIA3 P42263 3/20 0.43
▸ GRIA4 P48058 3/20 0.43
▸ GRIK2 Q13002 1/20 0.43
▸ GRIK3 Q13003 1/20 0.43
▸ GRIK4 Q16099 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7876588 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL197230 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL197231 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL7873502 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL7876596 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL29035113 1.00 DPP4 (0.50) DPP4CYP1A2CYP2D6ALOX15CYP2C19
Hydrochloric Acid SCHEMBL3418559 0.98 DPP4 (0.49) DPP4CYP1A2CYP2D6ALOX15CYP2C19
Hydrochloric Acid SCHEMBL7383848 0.98 DPP4 (0.49) DPP4CYP1A2CYP2D6ALOX15CYP2C19
Hydrochloric Acid SCHEMBL18103704 0.98 DPP4 (0.49) DPP4CYP1A2CYP2D6ALOX15CYP2C19
Hydrochloric Acid SCHEMBL3418556 0.98 DPP4 (0.49) DPP4CYP1A2CYP2D6ALOX15CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118271224-A Preparation method of (2S, 4S) -4-cyclohexyl-L-proline 浙江华海药业股份有限公司 2024-07-02 — — CN claimed
CN-114516825-A Method for preparing (2S,4S) -4-cyclohexyl-L-proline 浙江华海药业股份有限公司 2022-05-20 — — CN claimed
CN-110885358-A Vaccine for preventing tumor recurrence and metastasis and application method thereof 浙江爱睦世医学科技有限公司 2020-03-17 — — CN claimed
CN-104744511-A Fosinopril production method ZHANG YUN 2015-07-01 — — CN claimed
US-7078532-B2 Process for manufacture of fosinopril sodium LUPIN LABORATORIES LIMITED (IN) 2006-07-18 — — US claimed
US-20040225127-A1 Process for manufacture of fosinopril sodium LUPIN LABORATORIES LIMITED (IN) 2004-11-11 — — US claimed
EP-1383779-A2 A PROCESS FOR MANUFACTURE OF FOSINOPRIL SODIUM LUPIN LABORATORIES LIMITED (IN) 2004-01-28 — — EP claimed
WO-2002088149-A2 A PROCESS FOR MANUFACTURE OF FOSINOPRIL SODIUM LUPIN LABORATORIES LIMITED (IN) 2002-11-07 — — WO claimed
EP-0437799-B1 The diastereoselective preparation of phosphinate esters SQUIBB & SONS INC (US) 1995-02-22 — — EP claimed
EP-0437799-A1 The diastereoselective preparation of phosphinate esters E.R. SQUIBB & SONS, INC. (US) 1991-07-24 — — EP claimed
US-5008399-A Reacting phosphinic acid ester with halo ester in presence of specific base in organic solvent, hydrogenating E. R. SQUIBB & SONS, INC. (US) 1991-04-16 — — US claimed
CN-114516825-B Method for preparing (2S, 4S) -4-cyclohexyl-L-proline 浙江华海药业股份有限公司 2026-05-08 — — CN disclosed
CN-114516825-B Method for preparing (2S, 4S) -4-cyclohexyl-L-proline 浙江华海药业股份有限公司 2026-05-08 — — CN disclosed
EP-4587433-A1 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS Takeda Pharmaceutical Company Limited (JP) 2025-07-23 — — EP disclosed
CN-118271224-A Preparation method of (2S, 4S) -4-cyclohexyl-L-proline 浙江华海药业股份有限公司 2024-07-02 — — CN disclosed
US-4588819-A Process and intermediates for preparing trans-4-substituted-s-prolines E. R. SQUIBB & SONS, INC. (US) 1986-05-13 — — US disclosed
EP-0159156-A1 Hydroxy substituted ureido amino and imino acids E.R. Squibb & Sons, Inc. (US) 1985-10-23 — — EP disclosed
US-4535176-A HYPOTENSIVE AGENTS, ANALGESICS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS E. R. SQUIBB & SONS, INC. (US) 1985-08-13 — — US disclosed
US-4501901-A Method for making substituted prolines E. R. SQUIBB & SONS, INC. (US) 1985-02-26 — — US disclosed
US-4470973-A HYPOTENSIVE AGENTS, ANALGESICS E. R. SQUIBB & SONS, INC. (US) 1984-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040225127-A1 Process for manufacture of fosinopril sodium FOS, FOSB, AGT DPP4 194/4885CYP1A2 457/4885CYP2D6 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.